Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

5Aza and TSA treatment of MCF7 cells (BS-seq)

ABSTRACT: 5Aza and TSA treatment of MCF7 cells (BS-seq)

PROVIDER: PRJEB10087 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR974917_1.fastq.gz	Fastqsanger.gz
	ERR974917_2.fastq.gz	Fastqsanger.gz
	ERR974918_1.fastq.gz	Fastqsanger.gz
	ERR974918_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 4 of 4

Similar Datasets

5Aza and TSA treatment of MCF7 cells (BS-seq)

Project description:The goal of this study is to identify the DNA methylation changes caused by exposure of to the DNMT inhibitor 5-aza-2â-deoxycytidine (5Aza) and HDAC inhibitor Trichostatin A (TSA). We performed whole-genome bisulfite sequencing of the drug-treated MCF7 breast cancer cell lines and compare their DNA methylation profile with the untreated MCF7 (see E-MTAB-2014). While MCF7 treated with both drugs experienced global loss of DNA methylation, the 5Aza induced stronger demethylation than TSA.

2016-06-30 | E-MTAB-3785 | biostudies-arrayexpress

5Aza and TSA treatment of MCF7 cells (RNA-seq)

Project description:The goal of this study is to identify the gene expression changes caused by exposure of to the DNMT inhibitor 5-aza-2'-deoxycytidine (5Aza) and HDAC inhibitor Trichostatin A (TSA). We performed rRNA-depleted RNA sequencing of the untreated and drug-treated MCF7 breast cancer cell lines and carried out differential gene expression analysis. Although 5Aza caused a stranger demethylation effect than TSA, there were fewer differentially expressed gene in the 5Aza-treated MCF7 than the TSA-treated cells.

2016-06-30 | E-MTAB-3794 | biostudies-arrayexpress

5Aza and TSA treatment of MCF7 cells (RNA-seq)

Project description:5Aza and TSA treatment of MCF7 cells (RNA-seq)

| PRJEB10060 | ENA

Gene expression after TSA treatment in H69 cells

Project description:Objective of the study is to determine global changes in gene expression after HDAC inhibitor Trichostatin (TSA) treatment in H69 cell line

2021-05-26 | GSE161313 | GEO

Gene expression after TSA treatment in H69 cells

Project description:Gene expression after TSA treatment in H69 cells

| PRJNA677864 | ENA

7.5uM CG-1521 and 5uM TSA treatment of LNCaP Prostate Cancer cells

Project description:Genome wide expression changes following treatment with the HDACs (Histone Deacetylase Inhibitor) CG-1521 (7.5uM) or TSA (Trichostatin A) were investigated to determine regulatory targets and patterns of the HDAC Inhibitors. Keywords: Expression response to treatment, data was used for a comparison of gene expression and regulation between CG-1521 and TSA in LNCaP Cells

2007-09-15 | GSE8645 | GEO

Gene expression change after Enzalutamide treatment in MCF7 cells

Project description:To explore the mechanism of action of Enzalutamide, we performed RNA-seq to investigate gene expression difference after Enzalutamide treatment in both MCF7 and MCF7 with AR over expression (AROE) cells. RNA-sequencing (RNA-seq) of MCF7 and MCF7 AROE cells with DMSO or Enzalutamide treatment

2022-11-28 | GSE200435 | GEO

Transcriptional changes in MCF7 cells upon ISX treatment

Project description:Transcriptional changes in MCF7 cells upon ISX treatment

| PRJEB43758 | ENA

Gene expression analysis of mouse testis after treatment with histone deacetylase inhibitor TSA

Project description:Trichostatin A (TSA) is one of the most potent reversible histone deacetylase (HDAC) inhibitors. In male mice, subcutaneous application of TSA is followed by infertility due to apoptosis of pachytene spermatocytes. To get more insight into the mechanisms underlying this phenomenon, we performed a genome-wide expression analysis of murine testes after TSA treatment. The whole genome transcriptome analysis revealed 507 significantly regulated genes. Validation by real-time quantitative PCR confirmed the expression of 7 from 9 genes tested (78%). Keywords: time course

2007-08-02 | GSE5448 | GEO

7.5uM CG-1521 and 5uM TSA treatment of LNCaP Prostate Cancer cells

Project description:Genome wide expression changes following treatment with the HDACs (Histone Deacetylase Inhibitor) CG-1521 (7.5uM) or TSA (Trichostatin A) were investigated to determine regulatory targets and patterns of the HDAC Inhibitors. LNCaP Prostate Cancer cells were treated for a period of 24h with either CG-1521 (7.5uM) or TSA (5uM) following a 24h seeding period. At the selected time point, total RNA was harvested from the cells for hybridization and analysis by Nimblgen Systems Inc using the homo sapiens gene expression array.

2007-09-15 | E-GEOD-8645 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data